STK11 and neuroendocrine carcinoma: It was proposed that the neuroendocrine carcinoma in the patient might be the type II pulmonary large‐cell neuroendocrine carcinoma, which is enriched for biallelic inactivation of TP53 and RB1, different from type I with biallelic TP53 and STK11/KEAP1 alterations.5